Home | Welcome to Contract Pharma   
Last Updated Saturday, April 19 2014
Print

Xencor Receives Janssen R&D Milestone



Published January 17, 2013
Xencor, Inc. has received a milestone payment from Janssen R&D for the use of Xencor's Xtend half-life extension technology in a therapeutic antibody. The companies had entered a technology license agreement in 2009. The antibody target and payment amount were not disclosed.
 
"There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On